Page 1 | Search Results | Blood | American Society of Hematology

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) after Idelalisib Therapy Discontinuation

Jacqueline C. Barrientos, MD, Manmeen Kaur, MD, Alexis Mark, Jaewon Chung, Nancy Driscoll, PA-C, Alison Bender, PA-C, Kanti R. Rai, MD

Blood (2015) 126 (23): 4155.

https://doi.org/10.1182/blood.V126.23.4155.4155

Published: 2015

Journal Articles

Improved Prognosis of Chronic Lymphocytic Leukemia (CLL) Patients with Increased IgVH Mutations May Reflect Greater Alteration of the B-Cell Receptor (BCR) Binding Site

Matthew Kaufman, MD, Xiao Yan, MD, PhD, Rajendra Damle, PhD, Nina Kohn, MS, Martin Lesser, PhD, Nancy Driscoll, R-PA, Christina Johnson, R-PA, Jahan Aghalar, Yehuda Lebowicz, MD, Kanti Rai, MD, Nicholas Chiorazzi, MD

Blood (2008) 112 (11): 3152.

https://doi.org/10.1182/blood.V112.11.3152.3152

Published: 2008

Journal Articles

Surprising Lack of Correlation between CD38 and Time to First Treatment in Chronic Lympocytic Leukemia.

Matthew S. Kaufman, MD, Rajendra Damle, PhD, Nina Kohn, MA, Christina Johnson, RPA-C, Nancy Driscoll, RPA-C, Angelica Caramanica, RPA-C, Yehuda Lebowicz, MD, Kai Tsao, MD, Nicholas Chiorazzi, MD, Kanti Rai, MD

Blood (2007) 110 (11): 2058.

https://doi.org/10.1182/blood.V110.11.2058.2058

Published: 2007

Journal Articles

A Combination of Rituxan, Cyclophosphamide and Dexamethasone (RCD) Results in Long-Lasting Responses in Autoimmune Anemia and Thrombocytopenia in CLL Patients: A Single Institution Study.

Matthew S. Kaufman, MD, Yehuda Z. Lebowicz, MD, Nancy Driscoll, RPA-C, Christina Johnson, RPA-C, Dale Janson, RPA-C, Angelica Caramanica, RPA-C, Rajasree Roy, MD, Neetu Radhakrishnan, MD, Dhaval Mehta, MD, Mark Hoffman, MD, Dilip Patel, MD, Nina Kohn, MBA,MA, Kanti R. Rai, MD

Blood (2006) 108 (11): 2832.

https://doi.org/10.1182/blood.V108.11.2832.2832

Published: 2006

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) after Idelalisib Therapy Discontinuation

Improved Prognosis of Chronic Lymphocytic Leukemia (CLL) Patients with Increased IgVH Mutations May Reflect Greater Alteration of the B-Cell Receptor (BCR) Binding Site

Surprising Lack of Correlation between CD38 and Time to First Treatment in Chronic Lympocytic Leukemia.

A Combination of Rituxan, Cyclophosphamide and Dexamethasone (RCD) Results in Long-Lasting Responses in Autoimmune Anemia and Thrombocytopenia in CLL Patients: A Single Institution Study.

Email alerts

ASH Publications

American Society of Hematology

Update search

Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) after Idelalisib Therapy Discontinuation

Improved Prognosis of Chronic Lymphocytic Leukemia (CLL) Patients with Increased IgVH Mutations May Reflect Greater Alteration of the B-Cell Receptor (BCR) Binding Site

Surprising Lack of Correlation between CD38 and Time to First Treatment in Chronic Lympocytic Leukemia.

A Combination of Rituxan, Cyclophosphamide and Dexamethasone (RCD) Results in Long-Lasting Responses in Autoimmune Anemia and Thrombocytopenia in CLL Patients: A Single Institution Study.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only